The premium was barely a whisper above the offer price
On February 3, 2025, Dr. Agarwal's Health Care Ltd completed the allotment phase of its public market debut, raising over Rs 3,000 crore for one of India's larger eye care networks. Yet the grey market — that informal anteroom where price discovery begins before official trading — offered a nearly imperceptible premium, whispering that the stock might arrive at its listing not with fanfare but with quiet uncertainty. The story here is one familiar to markets: institutional conviction and retail hesitation pulling in opposite directions, leaving the true verdict to be written on February 5.
- Grey market shares traded at just Rs 402.5 against an issue price of Rs 402 — a 0.12% premium so thin it signals a flat or negative listing rather than the opening surge many IPO investors hope for.
- Institutional investors oversubscribed their portion 4.64 times, anchoring the deal with over Rs 875 crore committed even before the public window opened — a vote of professional confidence.
- Retail investors took up only 41% of their allotted shares and non-institutional investors filled just 39% of their quota, revealing a sharp divide between professional and ordinary investor conviction.
- The IPO closed 1.55 times subscribed overall, raising Rs 3,027 crore — but the bulk of that raise, Rs 2,727 crore, went to existing shareholders exiting rather than fresh capital entering the business.
- Investors awaited allotment results via BSE, NSE, and registrar Kfin Technologies on February 3, with the market's first real judgment set to arrive when trading opened on February 5.
On the morning of February 3, 2025, Dr. Agarwal's Health Care Ltd completed the allotment of its initial public offering — a milestone for the eye care company's entry into public markets. But the grey market told a cautious story: unlisted shares were changing hands at Rs 402.5, barely above the upper price band of Rs 402, a premium of just 0.12 percent. The implication was clear — the stock was expected to open flat or even slip when official trading began on February 5.
The offering itself had drawn meaningful interest. Running from January 29 through January 31, it attracted bids for more than 8.29 crore shares against 5.35 crore on offer, closing 1.55 times subscribed. The total raise reached Rs 3,027.26 crore — Rs 300 crore in fresh capital and Rs 2,727.26 crore in promoter and shareholder exits. Anchor investors had committed over Rs 875.5 crore before the public window even opened.
Yet the subscription pattern revealed a divided market. Qualified institutional buyers oversubscribed their portion 4.64 times, while retail investors took up only 41 percent of their allotted shares and non-institutional investors filled just 39 percent of their quota. Professional money saw value; ordinary investors held back.
Dr. Agarwal's Health Care operates 193 eye care facilities across India, concentrated in southern cities like Chennai, Hyderabad, and Bengaluru, offering surgeries, optical products, and pharmaceuticals. The fresh capital raised was earmarked for debt repayment and future acquisitions. As allotment results became available through BSE, NSE, and registrar Kfin Technologies, investors braced for a listing that the grey market suggested would offer little drama — a company arriving, perhaps, at exactly what it was worth.
On the morning of February 3, 2025, the allotment process for Dr. Agarwal's Health Care Ltd's initial public offering moved forward as scheduled, marking a milestone for the eye care company's entry into public markets. Yet the signals from the grey market—where unlisted shares trade among investors before official listing—told a cautious story. Those shares were changing hands at Rs 402.5 each, barely a whisper above the upper price band of Rs 402. The premium was just 0.12 percent, a figure so thin it suggested the market expected the stock to open flat or even decline when trading began on February 5.
The IPO itself had drawn substantial investor interest. The offering, which ran from January 29 through January 31, pulled in bids for more than 8.29 crore shares against 5.35 crore on offer—a subscription ratio of 1.55 times by the final day. The total raise came to Rs 3,027.26 crore, a combination of Rs 300 crore in fresh capital and Rs 2,727.26 crore in shares sold by promoters and existing shareholders. Before the public window even opened, anchor investors had committed over Rs 875.5 crore, signaling institutional confidence in the company's fundamentals.
But the subscription pattern revealed a split in the market's conviction. Qualified institutional buyers—the large funds and investment firms—had rushed in, oversubscribing their portion 4.64 times. Retail individual investors, by contrast, showed restraint, taking up only 41 percent of their allotted shares. Non-institutional investors filled just 39 percent of their quota. The divergence mattered: it suggested that while professional money managers saw value, ordinary investors remained skeptical or cautious.
Dr. Agarwal's Health Care operates 193 eye care facilities across India, with the heaviest concentration in the south—Chennai, Hyderabad, and Bengaluru—and a growing presence in the west. The company offers everything from cataract and refractive surgeries to optical products and pharmaceutical items. It is, by any measure, a substantial player in a growing sector. The fresh capital raised would go toward debt repayment and general corporate purposes, with room for acquisitions down the line.
On the afternoon of February 3, investors could begin checking whether their applications had been selected. The BSE and NSE websites, along with the registrar Kfin Technologies, would display allotment status. Bank debit messages would follow for those who received shares. The listing itself was set for two days later, on February 5, when the market would render its first real judgment. The grey market premium—that thin 0.12 percent—suggested investors should not expect a dramatic opening pop. What they might see instead was a company arriving at fair value, or possibly below it, a reality that would test whether the institutional enthusiasm could hold once retail trading began.
Notable Quotes
The grey market premium is very low at 0.12 percent, suggesting a flat or negative listing— Market observers
The Hearth Conversation Another angle on the story
The subscription numbers look strong—1.49 times overall. Why does the grey market premium matter so much if the IPO itself was oversubscribed?
Because subscription and listing performance are two different things. Subscription tells you how many people wanted in at the offered price. Grey market premium tells you what those same people think the stock is actually worth once they own it. A 0.12 percent premium is essentially saying: we got what we paid for, nothing more.
So the institutions oversubscribed 4.64 times, but retail investors were lukewarm. What does that split mean?
It means the big money saw a solid business and moved fast. Retail investors either didn't have conviction or didn't have the information to feel confident. That's a warning sign for listing day—if retail doesn't show up to buy, there's no one to push the price higher.
The company operates 193 facilities, mostly in the south. Is that a strength or a limitation?
It's both. Deep roots in high-growth markets like Bangalore and Hyderabad is a strength. But concentration in the south means less geographic diversification than a pan-India player might have. Growth will depend on how fast they can expand westward.
What happens if the stock opens below the issue price on February 5?
Then the anchor investors and early subscribers lose money immediately. It signals the market thinks the company was priced too high or that sentiment has shifted. It also makes future capital raises harder.
Is there anything in the fundamentals that would justify the grey market's caution?
The grey market doesn't usually care about fundamentals—it's pure sentiment and momentum. But if institutional buyers are confident and retail is not, that's a sign the story hasn't reached ordinary investors yet. Maybe the company needs to do more to explain why eye care is a growth business.